Expert Interview
Unveiling the Potential of AFM24 in EGFR-Wildtype Non-Small Cell Lung Cancer: Insights from the AFM24-102 Phase 1/2a Study
Ticker(s): AFMDAn oncologist or lung cancer specialist with expertise in NSCLC and experience in clinical trials. The expert should have a deep understanding of NSCLC treatment, especially in the context of EGFR-wildtype cases, and be familiar with the latest advancements in immunotherapy and targeted treatments.
AFM24 is described as a tetravalent, bispecific innate cell engager (ICE). Could you elaborate on how its unique mechanism of action contributes to its efficacy in treating EGFR-wildtype NSCLC?
Added By: catalin_adminWith the AFM24-102 study showing 1 complete response and 2 partial responses in the EGFRwt NSCLC cohort, what does this indicate about the potential of AFM24 in treating heavily pre-treated NSCLC patients?"
Added By: catalin_adminConsidering that all patients in the study progressed on PD-[L]1 targeted therapy, how does AFM24's performance compare with these prior treatments in terms of efficacy and safety?
Added By: catalin_adminWhat are the criteria for selecting patients for AFM24 treatment in NSCLC, and how does EGFR-wildtype status influence these decisions?
Added By: catalin_adminAFM24 is being evaluated in combination with atezolizumab. What is the rationale behind this combination, and what synergistic effects might it have?
Added By: catalin_adminDr. Andreas Harstrick mentioned a significant unmet need for patients who have exhausted all previous lines of therapy. How does AFM24 aim to fulfill this need?
Added By: catalin_adminWith plans to expand the study to 40 EGFRwt NSCLC patients, what are the expected outcomes, and how might this influence the future direction of AFM24's clinical development?
Added By: catalin_adminBased on the current data, what can be inferred about the long-term safety and tolerability of AFM24 for NSCLC patients, and what are the key factors to monitor in ongoing and future studies?
Added By: catalin_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
